REFERENCES

1. 1. Kondili LA, Monti M, Quaranta MG, Gragnani L, Panetta V, Brancaccio G, et al. A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. Hepatology. 2022;76:220-32.
2. 1. Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64:1473-82.
3. 1. Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16(5):523-41. https://doi.org/10.1016/j.autrev.2017.03.004
4. 1. Fayed A, Hegazy MT, Biard L, Vieira M, El Shabony T, Saadoun D, et al. Relapse of HCV-cryoglobulinemic vasculitis following sustained viral response after interferon-free direct-acting antivirals. Am J Gastroenterol. 2022. https://doi.org/10.14309/ajg.0000000000001667
5. 1. Gragnani L, Lorini S, Marri S, Basile U, Santarlasci V, Monti M, et al. Hematological and genetic markers in the rational approach to patients with HCV sustained virological response with or without persisting cryoglobulinemic vasculitis. Gragnani. 2021;74:1164-73.